Table 4.
Representative chemical drugs-based combination strategies for anti-inflammatory nanotherapeutics.
| Platform | Drug 1 | Drug 2 | Route | Animal models | Mechanism | Year | Refs. |
|---|---|---|---|---|---|---|---|
|
Cationic polypeptide nanomicelles |
Losmapimod | Tempo | Topical | Dry eye mouse model- | Scavenge ROS; Suppress MAPK signal pathway |
2022 | 261 |
| ROS-responsive prodrug nanomicelles | Dexamethasone | Artesunate | I.V. | Adjuvant-induced arthritis rat model | Scavenge ROS; Suppress HIF-1α/NF-κB signal pathway; Enhance M2-type macrophage polarization |
2022 | 262 |
| mPEG-b-PCL nanomicelles | 9-aminoacridine | Caffeic acid | I.V. | CIA rat model | Suppress HIF-1α/NF-κB signal pathway | 2022 | 187 |
| Self-assembled peptide hydrogel | 3,5-dihydroxybenzoic acid | Ibuprofen | I.V. | Endotoxin-induced uveitis rabbit model | Scavenge ROS; Suppress pro-inflammatory factors (e.g., IL-1β, IL-6 and TNF-α); Suppress NF-κB and JAK-STAT signal pathways |
2022 | 263 |
| Injectable polymeric aggregate-embodied copolymer hydrogel | Dexamethasone | Tempo | Intra-articular injection | RA mouse model | Scavenge RNS an ROS; Upregulate immune cells |
2021 | 264 |